Details of the Drug

General Information of Drug (ID: DMAHJEF)

Drug Name

Betamethasone

Synonyms

betamethasone; 378-44-9; Betadexamethasone; Flubenisolone; Betamethazone; Rinderon; Visubeta; Celestene; Betnelan; Betapredol; Betacortril; Betacorlan; Methazon; Betsolan; Betamamallet; Hormezon; Betasolon; Betametasone; Cidoten; Bebate; Bedifos; Becort; beta-Methasone; Desacort-Beta; Rinderon A; beta-Methasone alcohol; Betametasona; Betafluorene; Betamethasonum; Celestone; Betamethasone cream; Betamethasone alcohol; Betametasone [DCIT]; 9alpha-Fluoro-16beta-methylprednisolone; Celestone Syrup and Tablets; Celeston; Celestona; Cellestoderm; Luxiqo; Betamethasone Base; Betamethasone Valearate; Betamethasonvalerat Mikron; LT00441022; SCH 4831; Beta-Methasone; Beta-Methasone alcohol; Betametasona [INN-Spanish]; Betamethasonum [INN-Latin]; Betnovate (TN); Celestone (TN); Diprolene (TN); Diprosone (TN); Lotrisone (TN); Rinderon (TN); SCH-4831; Betamethasone (JP15/USP/INN); Betamethasone [USAN:BAN:INN:JAN]; Betamethasone [USAN:INN:BAN:JAN]; Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone; 1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol; 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione; 9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione; 9-Fluoro-16beta-methylprednisolone; 9-alpha-Fluoro-16-beta-methylprednisolone; 9alpha-Fluoro-16 beta-methyl-prednisolone; Betamethasone sodium phosphate

Indication

Disease Entry	ICD 11	Status	REF
Acute adrenal insufficiency	N.A.	Approved	[1]
Addison disease	5A74.0	Approved	[1]
Allergic rhinitis	CA08.0	Approved	[1]
Angioedema	4A00.15	Approved	[1]
Aspiration pneumonitis	N.A.	Approved	[1]
Autoimmune haemolytic anaemia	3A20	Approved	[1]
Bursitis	N.A.	Approved	[1]
Cerebral edema	8D60.1	Approved	[1]
Congenital adrenal hyperplasia	5A71.01	Approved	[1]
Crohn disease	DD70	Approved	[1]
Dermatitis herpetiformis	EB44	Approved	[1]
Diamond-Blackfan anemia	N.A.	Approved	[1]
Disorder of orbital region	N.A.	Approved	[1]
Epicondylitis	N.A.	Approved	[1]
Erythema multiforme	N.A.	Approved	[1]
Exanthem	N.A.	Approved	[1]
Granuloma annulare	N.A.	Approved	[1]
Inflammation	1A00-CA43.1	Approved	[2]
Inflammatory bowel disease	DD72	Approved	[1]
Miliary tuberculosis	N.A.	Approved	[1]
Multiple sclerosis	8A40	Approved	[1]
Mycosis fungoides	2B01	Approved	[1]
Primary cutaneous T-cell lymphoma	N.A.	Approved	[1]
Psoriasis	EA90	Approved	[1]
Psoriatic arthritis	FA21	Approved	[1]
Rheumatic heart disease	N.A.	Approved	[1]
Sarcoidosis	4B20.5	Approved	[1]
Scalp dermatosis	N.A.	Approved	[1]
Serum sickness	N.A.	Approved	[1]
Severe asthma	CA23	Approved	[1]
Skin disease	EA00-EM0Z	Approved	[1]
Systemic lupus erythematosus	4A40.0	Approved	[1]
Tinea corporis	1F28.Y	Approved	[1]
Tinea cruris	1F28.3	Approved	[1]
Acquired thrombocytopenia	N.A.	Investigative	[1]
Asthma	CA23	Investigative	[1]
Beta-thalassemia major	N.A.	Investigative	[1]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Follicular lymphoma	2A80	Investigative	[1]
Rheumatoid arthritis	FA20	Investigative	[1]
Synovitis	N.A.	Investigative	[1]
Tinea pedis	1F28.2	Investigative	[1]
Trichinellosis	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

392.5

Logarithm of the Partition Coefficient (xlogp)

1.9

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The clearance of drug is 6,466 +/- 805 mL/h [4]
Elimination: 4.8% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 10.2 +/- 2.5 hours [4]
Metabolism: The drug is metabolized via removal of the side chain [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.38219 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.36% [7]
Vd: The volume of distribution (Vd) of drug is 94.584 +/- 23.539 L [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.066 mg/mL [3]

Chemical Identifiers

Formula: C22H29FO5
IUPAC Name: (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES: C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
InChI: InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
InChIKey: UREBDLICKHMUKA-DVTGEIKXSA-N

Cross-matching ID

PubChem CID: 9782
ChEBI ID: CHEBI:3077
CAS Number: 378-44-9
DrugBank ID: DB00443
TTD ID: D0CW1P
VARIDT ID: DR01392
ACDINA ID: D00879

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Agonist	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Regulation of Drug Effects	[10]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[11]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Gene/Protein Processing	[11]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Gene/Protein Processing	[11]
Early growth response protein 1 (EGR1)	OTCP6XGZ	EGR1_HUMAN	Gene/Protein Processing	[12]
Frataxin, mitochondrial (FXN)	OTE9U09A	FRDA_HUMAN	Gene/Protein Processing	[13]
Glucocorticoid receptor (NR3C1)	OTCI2YDI	GCR_HUMAN	Gene/Protein Processing	[14]
Mineralocorticoid receptor (NR3C2)	OT0F2V2Z	MCR_HUMAN	Gene/Protein Processing	[14]
Vascular endothelial growth factor A, long form	OTIM9MZ3	VEGFA_HUMAN	Gene/Protein Processing	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Betamethasone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[15]
Ketorolac	DMI4EL5	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Ketorolac.	Postoperative inflammation [1A00-CA43]	[16]
Bromfenac	DMKB79O	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Bromfenac.	Postoperative inflammation [1A00-CA43]	[16]
-----------

Coadministration of a Drug Treating the Disease Different from Betamethasone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Betamethasone due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[17]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Betamethasone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[18]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Betamethasone caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[19]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Betamethasone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[19]
Levalbuterol	DM5YBO1	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Levalbuterol.	Asthma [CA23]	[20]
Terbutaline	DMD4381	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Terbutaline.	Asthma [CA23]	[19]
Pirbuterol	DMI5678	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Pirbuterol.	Asthma [CA23]	[19]
Salbutamol	DMN9CWF	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Salbutamol.	Asthma [CA23]	[20]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Roflumilast.	Asthma [CA23]	[21]
Formoterol	DMSOURV	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Formoterol.	Asthma [CA23]	[19]
Ofloxacin	DM0VQN3	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Betamethasone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Betamethasone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Trovafloxacin	DM6AN32	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Sparfloxacin	DMB4HCT	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Gemifloxacin	DMHT34O	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Norfloxacin	DMIZ6W2	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
ABT-492	DMJFD2I	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and ABT-492.	Bacterial infection [1A00-1C4Z]	[22]
Levofloxacin	DMS60RB	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Betamethasone caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Lomefloxacin	DMVRH9C	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Betamethasone caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Betamethasone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Betamethasone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[19]
Vilanterol	DMF5EK1	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Salmeterol	DMIEU69	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Indacaterol	DMQJHR7	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Arformoterol	DMYM974	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[19]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Phenylbutazone.	Chronic pain [MG30]	[16]
Isoproterenol	DMK7MEY	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Isoproterenol.	Conduction disorder [BC63]	[20]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Betamethasone and Mivacurium.	Corneal disease [9A76-9A78]	[19]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Betamethasone and Pancuronium.	Corneal disease [9A76-9A78]	[19]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Betamethasone and Tubocurarine.	Corneal disease [9A76-9A78]	[19]
Mifepristone	DMGZQEF	Major	Antagonize the effect of Betamethasone when combined with Mifepristone.	Cushing syndrome [5A70]	[25]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Betamethasone caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[26]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Betamethasone due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[27]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Betamethasone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[28]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Betamethasone caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[29]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Betamethasone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[19]
Primidone	DM0WX6I	Moderate	Increased metabolism of Betamethasone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Betamethasone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Betamethasone caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Betamethasone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[33]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Betamethasone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Betamethasone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Betamethasone caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[32]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Betamethasone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[30]
Carbamazepine	DMZOLBI	Moderate	Increased metabolism of Betamethasone caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Mefenamic acid.	Female pelvic pain [GA34]	[16]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Betamethasone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[35]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Betamethasone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[19]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Betamethasone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[19]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Betamethasone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[19]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Betamethasone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[36]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Betamethasone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[37]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Betamethasone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[38]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Betamethasone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Betamethasone caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Betamethasone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Betamethasone caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Betamethasone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Betamethasone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[40]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Betamethasone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Betamethasone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Betamethasone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Betamethasone caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[41]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Betamethasone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[42]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Betamethasone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[19]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[43]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Betamethasone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[30]
Methotrexate	DM2TEOL	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Methotrexate.	Leukaemia [2A60-2B33]	[44]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Denosumab.	Low bone mass disorder [FB83]	[45]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Betamethasone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[19]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Betamethasone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[46]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Betamethasone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[21]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Betamethasone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[19]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Betamethasone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[47]
Nivolumab	DMAB9QE	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Nivolumab.	Melanoma [2C30]	[19]
Pembrolizumab	DMFQEA6	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Pembrolizumab.	Melanoma [2C30]	[19]
Ipilimumab	DMJTIYK	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Ipilimumab.	Melanoma [2C30]	[19]
Cemiplimab	DMKMJHE	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Cemiplimab.	Melanoma [2C30]	[19]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Betamethasone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[21]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Betamethasone and Thalidomide.	Multiple myeloma [2A83]	[48]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Tecfidera.	Multiple sclerosis [8A40]	[49]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Betamethasone and Siponimod.	Multiple sclerosis [8A40]	[20]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Betamethasone and Fingolimod.	Multiple sclerosis [8A40]	[50]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Ocrelizumab.	Multiple sclerosis [8A40]	[51]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Betamethasone and Ozanimod.	Multiple sclerosis [8A40]	[21]
Rifabutin	DM1YBHK	Moderate	Increased metabolism of Betamethasone caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[52]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Betamethasone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[19]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Betamethasone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[53]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Betamethasone caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[54]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[55]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Betamethasone and Bupropion.	Nicotine use disorder [6C4A]	[56]
Atezolizumab	DMMF8U0	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Atezolizumab.	Non-small cell lung cancer [2C25]	[19]
Rofecoxib	DM3P5DA	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Rofecoxib.	Osteoarthritis [FA00-FA05]	[16]
Valdecoxib	DMAY7H4	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Valdecoxib.	Osteoarthritis [FA00-FA05]	[16]
Diclofenac	DMPIHLS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Diclofenac.	Osteoarthritis [FA00-FA05]	[16]
Naproxen	DMZ5RGV	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Naproxen.	Osteoarthritis [FA00-FA05]	[16]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Betamethasone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[57]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Aspirin.	Pain [MG30-MG3Z]	[58]
Diflunisal	DM7EN8I	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Diflunisal.	Pain [MG30-MG3Z]	[16]
Ibuprofen	DM8VCBE	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Ibuprofen.	Pain [MG30-MG3Z]	[16]
Nabumetone	DMAT2XH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Nabumetone.	Pain [MG30-MG3Z]	[16]
Piroxicam	DMTK234	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Piroxicam.	Pain [MG30-MG3Z]	[16]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Betamethasone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[59]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Betamethasone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[60]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Betamethasone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[19]
Ritodrine	DM4V6RL	Minor	Increased risk of hypokalemia by the combination of Betamethasone and Ritodrine.	Preterm labour/delivery [JB00]	[19]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Betamethasone caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[61]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Betamethasone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[62]
Gatifloxacin	DMSL679	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[22]
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Salsalate.	Rheumatoid arthritis [FA20]	[15]
Meloxicam	DM2AR7L	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Meloxicam.	Rheumatoid arthritis [FA20]	[16]
Sulindac	DM2QHZU	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Sulindac.	Rheumatoid arthritis [FA20]	[16]
Celecoxib	DM6LOQU	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Celecoxib.	Rheumatoid arthritis [FA20]	[16]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Canakinumab.	Rheumatoid arthritis [FA20]	[63]
Oxaprozin	DM9UB0P	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Oxaprozin.	Rheumatoid arthritis [FA20]	[16]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Rilonacept.	Rheumatoid arthritis [FA20]	[63]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Flurbiprofen.	Rheumatoid arthritis [FA20]	[16]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Betamethasone and Golimumab.	Rheumatoid arthritis [FA20]	[64]
Fenoprofen	DML5VQ0	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Fenoprofen.	Rheumatoid arthritis [FA20]	[16]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Betamethasone and Leflunomide.	Rheumatoid arthritis [FA20]	[42]
Tolmetin	DMWUIJE	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Tolmetin.	Rheumatoid arthritis [FA20]	[16]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[58]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Betamethasone when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[65]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Betamethasone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[19]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Betamethasone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[21]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Betamethasone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Armodafinil	DMGB035	Minor	Increased metabolism of Betamethasone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[66]
LEE011	DMMX75K	Moderate	Decreased metabolism of Betamethasone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[67]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Betamethasone and Pitolisant.	Somnolence [MG42]	[21]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Betamethasone due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[68]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Betamethasone and Pipecuronium.	Tonus and reflex abnormality [MB47]	[19]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Betamethasone and Doxacurium.	Tonus and reflex abnormality [MB47]	[19]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Betamethasone and Vecuronium.	Tonus and reflex abnormality [MB47]	[19]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Betamethasone and Rocuronium.	Tonus and reflex abnormality [MB47]	[19]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Betamethasone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[62]
Durvalumab	DM4PVDY	Moderate	Additive immunosuppressive effects by the combination of Betamethasone and Durvalumab.	Ureteral cancer [2C92]	[19]
Cinoxacin	DM4EWNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Cinoxacin.	Urinary tract infection [GC08]	[22]
Nalidixic acid	DMRM0JV	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Nalidixic acid.	Urinary tract infection [GC08]	[22]
Enoxacin	DMYTE6L	Major	Increased risk of tendinitis/tendon rupture by the combination of Betamethasone and Enoxacin.	Urinary tract infection [GC08]	[22]
-----------


⏷ Show the Full List of 143 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Cetyl alcohol	E00061	2682	Coating agent; Emollient; Emulsifying agent; Stiffening agent
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Phosphoric acid	E00039	1004	Acidulant; Buffering agent
Chlorocresol	E00051	1732	Antimicrobial preservative
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent
Polyethylene glycol 1000	E00647	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium citrate	E00225	13344	Alkalizing agent; Buffering agent; Complexing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol monostearate	E00239	14878	Emollient; Emulsifying agent; Surfactant
Sodium dihydrogenorthophosphate	E00559	23672064	Buffering agent; Complexing agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Sodium phosphate monobasic monohydrate	E00428	516949	Buffering agent; Complexing agent
Stearyl alcohol	E00172	8221	Emollient; Emulsifying agent; Stiffening agent; Viscosity-controlling agent
Water	E00035	962	Solvent
Butane	E00155	7843	Aerosol propellant
Cyclomethicone	E00203	10913	Emollient; Humectant; Viscosity-controlling agent
Polyoxyl 20 cetyl ether	E00452	2724259	Emulsifying agent; Ointment base; Solubilizing agent; Surfactant
Propane	E00115	6334	Aerosol propellant
Sorbitan tristearate	E00516	17800859	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Polysorbate 60	E00715	Not Available	Dispersing agent; Emollient; Emulsifying agent; Surfactant; Plasticizing agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 20 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Betamethasone Valerate 0.1% cream	0.10%	Cream	Topical
Betamethasone 0.05% cream	0.05%	Cream	Topical
Betamethasone Valerate 0.12% aerosol	0.12%	Aerosol	Topical
Betamethasone 0.05% ointment	0.05%	Ointment	Topical

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Betamethasone FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7061).
3	BDDCS applied to over 900 drugs
4	Pharmacokinetics and Pharmacodynamics of Intramuscular and Oral Betamethasone and Dexamethasone in Reproductive Age Women in India. Clin Transl Sci. 2020 Mar;13(2):391-399. doi: 10.1111/cts.12724. Epub 2019 Dec 13.
5	Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83.
9	Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803.
10	Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
11	Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
12	[Steroid drugs and GM-CSF modulates activity of Egr-1 in glioma cells]. Cir Cir. 2013 Jan-Feb;81(1):3-13.
13	Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
14	Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
15	Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
16	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
17	Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
18	Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8. [PMID: 4553339]
19	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
20	Cerner Multum, Inc. "Australian Product Information.".
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
23	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
24	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
25	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
26	Cerner Multum, Inc. "Canadian Product Information.".
27	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
28	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
29	Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
30	Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
31	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
32	Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
33	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
34	Keitner GI, Fruzzetti AE, Miller IW, Norman WH, Brown WA "The effect of anticonvulsants on the dexamethasone suppression test." Can J Psychiatry 34 (1989): 441-3. [PMID: 2766197]
35	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
36	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
37	Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
38	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
39	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
40	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
41	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
42	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
43	Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4. [PMID: 6343871]
44	Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC "Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients." J Rheumatol 20 (1993): 263-7. [PMID: 8474062]
45	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
46	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
47	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
48	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
49	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
50	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
51	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
52	Bergrem H, Refvem OK "Altered prednisolone pharmacokinetics in patients treated with rifampicin." Acta Med Scand 213 (1983): 339-43. [PMID: 6880856]
53	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
54	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
55	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
56	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
57	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
58	Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
59	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
60	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
61	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
62	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
63	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
64	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
65	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
66	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
67	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
68	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.